Michael Keens, COO, and Lisa Gorman, VP, of Operations, discuss trends in patient centricity.
Firma Clinical Research's eBook explains how to recruit, engage and retain more patients to improve clinical trials.
Firma team members will be at Booth #1949 to discuss the company’s unique approach to patient-centric clinical trials.
Firma’s Michael Keens and Darcy Forman to Speak at MAGI’s Clinical Research Conference – 2019 East Program
Firma’s Michael Keens and Darcy Forman will speak at MAGI’s Clinical Research Conference - 2019 East on May 6.
PharmaVOICE Features Firma Clinical Research Executives Darcy Forman and Michael Keens’ Thoughts on Patient Engagement
Firma Clinical Research leadership figures, Darcy Forman and Michael Keens, were featured in the April 2019 edition of PharmaVOICE. Forman and Keens share information and perspective on patient-focused advancements in wearables, patient engagement liaisons and integrating patient input to reduce burden of treatment. Read the full article here.
In this article, Firma Clinical Research COO, Mike Keens, describes five steps you can take to fully harness patient centricity and ensure clinical trial success.
Firma Clinical Research is pleased to announce their selection as a 2018 Top Innovator by CenterWatch. Firma was recognized as part of the 25th anniversary special edition of CenterWatch Monthly for innovations to improve patient centricity and enhance the patient experience within clinical trials.
Firma Clinical Research is pleased to announce the successful completion of their externally validated ISO 9000:2015 recertification process by the NQA, one of the leading ASQ National Accreditation Board (ANAB) accredited registrars for ISO certifications.
Firma Clinical Research is pleased to announce being awarded the 2017 Outstanding Small and Medium Enterprise award by the Small and Medium Enterprise Administration (SMEA) of the Ministry of Economic Affairs of Taiwan.
Firma Clinical Research, an ISO quality management-certified clinical research organization (CRO), is pleased to announce its contribution to the FDA approval of Melinta Therapeutics’ lead antibiotic, Baxdela™ (delafloxacin), for the treatment of acute bacterial skin and skin structure infections (ABSSSI) caused by susceptible bacteria.